| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Amylose does not have a defined biological target as a therapeutic agent. It is a polysaccharide used as a food ingredient and as a pharmaceutical excipient. The compound is not intended to exert pharmacological effects. Its utility lies in its physical properties as a thickening and gelling agent. In the body, it is digested by amylase enzymes to glucose. |
|---|---|
| ln Vitro |
In vitro, Amylose is hydrolyzed by α-amylase enzymes to maltose and glucose. Its digestion kinetics can be studied using enzymatic assays. The compound is used as a substrate for studying starch digestion and amylase activity. It is not characterized for direct biological activities such as enzyme inhibition or receptor modulation.
|
| ln Vivo |
Amylose is not used for in vivo pharmacological activity assessment as a drug compound. It is a food ingredient and pharmaceutical excipient. In vivo, it is digested to glucose and absorbed. Its effects on blood glucose levels are studied in metabolic research. It is not intended to be administered for therapeutic purposes.
|
| Enzyme Assay |
In vitro enzyme assays for Amylose typically involve measuring its hydrolysis by α-amylase or other amylolytic enzymes. The compound is incubated with the enzyme in a buffered solution, and the release of reducing sugars is measured using colorimetric methods such as the dinitrosalicylic acid (DNS) assay. Standard biochemical protocols are employed for its use.
|
| Cell Assay |
Amylose is used in cell-based assays to study glucose metabolism and cellular uptake. Cells are treated with amylose or its digestion products to assess metabolic responses. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are employed. However, it is not characterized as a pharmacological agent for direct cellular effects.
|
| Animal Protocol |
Amylose is used in animal studies to evaluate its effects on postprandial blood glucose, insulin response, and digestive enzyme activity. The compound is administered orally to rodents, and blood glucose and insulin levels are measured over time. These studies are used to assess the glycemic impact of starch. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
Amylose is a linear polysaccharide composed of α-D-glucose units linked by α(1→4) glycosidic bonds. It has a molecular weight of approximately 10⁵ to 10⁶ Da. It is a white powder that is sparingly soluble in water. The compound is used as a food ingredient, thickening agent, and pharmaceutical excipient. It is typically stored under standard laboratory conditions.
|
| Toxicity/Toxicokinetics |
Amylose is generally recognized as safe (GRAS) for use as a food ingredient. It is not intended for human therapeutic use as a drug substance. As a research chemical, standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound is typically well-tolerated.
|
| Additional Infomation |
α-Malttriose is a maltotriose trisaccharide with a pyranose ring at the reducing end and an α-configuration at the terminal carbon atom. It is a human metabolite. Amylose is being studied in the clinical trial NCT01027325 (resistant starch insulin sensitivity test). Maltotriose is a metabolite present in or produced by Escherichia coli (K12 strain, MG1655 strain). α-Malttriose has been reported in Drosophila melanogaster, humans, and other organisms with relevant data. See also: Maltotriose (note moved to).
Amylose (CAS#: 9005-82-7) is a linear polysaccharide composed of α-D-glucose units linked by α(1→4) glycosidic bonds. It is one of the two components of starch and is used as a food ingredient, thickening agent, and pharmaceutical excipient. This compound is not a drug and is a polysaccharide. |
| Molecular Formula |
C18H32O16
|
|---|---|
| Molecular Weight |
504.4371
|
| Exact Mass |
504.169
|
| CAS # |
9005-82-7
|
| PubChem CID |
192826
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
865.2±65.0 °C at 760 mmHg
|
| Melting Point |
273ºC-275ºC (dec.)
|
| Flash Point |
477.0±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.673
|
| LogP |
-3.25
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
641
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)O)O
|
| InChi Key |
FYGDTMLNYKFZSV-PXXRMHSHSA-N
|
| InChi Code |
InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9824 mL | 9.9120 mL | 19.8240 mL | |
| 5 mM | 0.3965 mL | 1.9824 mL | 3.9648 mL | |
| 10 mM | 0.1982 mL | 0.9912 mL | 1.9824 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
